Phase I/II study of zotiraciclib for recurrent malignant gliomas with IDH mutations: results of the phase I study (SNO 2025) - Dec 2, 2025 - Abstract #CTNI-27; Pres time: Nov 22, 2025; 11:45 AM - 12:45 PM; Location: Hawaii Convention Center, Kamehameha Exhibit Hall II & III; "ZTR at the RP2D of 200mg, q3D, 3wks on/1wk off in a 28-day cycle is well tolerated. Objective responses suggest activity of this regimen in IDH-mutant gliomas, supporting continued investigation."
P1/2 data • Brain Cancer • Glioma • High Grade Glioma • Solid Tumor
|
|
Christine McGowan; Qi Li; Keith Schmidt; Tryston Metz; Kelly Fernadez; Tina Pillai; Peng Lu; Ewa Grajkowska; Lisa Boris; Renee Tweneboah Koduah; Jennifer Reyes; Eric Burton; Bryam Ozer; Brett Theeler; Mark Gilbert; William Figg; Ying Yuan; Jing Wu
|